摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(2-吡啶基氧基)乙胺 | 29450-07-5

中文名称
2-(2-吡啶基氧基)乙胺
中文别名
2-(2-吡啶氧基)乙胺
英文名称
2-(pyridin-2-yloxy)ethanamine
英文别名
2-(pyridin-2-yloxy)-ethylamine;2-(2-pyridyloxy)ethylamine;2-aminoethoxy-2-pyridine;2-(2-pyridinyloxy)ethaneamine;2-(pyridin-2-yloxy)ethylamine;2-pyridin-2-yloxyethanamine
2-(2-吡啶基氧基)乙胺化学式
CAS
29450-07-5
化学式
C7H10N2O
mdl
——
分子量
138.169
InChiKey
TUVONOFKFDJHBJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    216-222 °C
  • 沸点:
    238 °C
  • 密度:
    1.089±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.5
  • 重原子数:
    10
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.29
  • 拓扑面积:
    48.1
  • 氢给体数:
    1
  • 氢受体数:
    3

安全信息

  • 海关编码:
    2933399090
  • 危险性防范说明:
    P305+P351+P338
  • 危险性描述:
    H302,H319
  • 储存条件:
    室温且干燥

SDS

SDS:db7080ec65515711c8ab57945e6acc99
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 2-(Pyridin-2-yloxy)ethanamine
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 2-(Pyridin-2-yloxy)ethanamine
CAS number: 29450-07-5

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H10N2O
Molecular weight: 138.2

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-(2-吡啶基氧基)乙胺四丁基溴化铵 sodium hydroxide三乙胺 作用下, 以 四氢呋喃甲苯 为溶剂, 反应 56.0h, 生成 Bis-(5,5'-dimethyl-1'-vinyl-1'H-[1,3']bipyrazolyl-3-ylmethyl)-[2-(pyridin-2-yloxy)-ethyl]-amine
    参考文献:
    名称:
    Synthesis and ionophore properties of a series of new tetrapyrazolic macrocycles
    摘要:
    DOI:
    10.1016/s0040-4020(01)85096-1
  • 作为产物:
    描述:
    参考文献:
    名称:
    Quinoline derivatives as antibacterials
    摘要:
    Aminopiperidine衍生物及其药学上可接受的衍生物,在哺乳动物中,特别是人类中,用于治疗细菌感染的方法中是有用的。
    公开号:
    US20040053928A1
点击查看最新优质反应信息

文献信息

  • Substituted 4-amino[1,2,4]triazolo[4,3-a] quinoxalines
    申请人:Pfizer Inc.
    公开号:US20040192698A1
    公开(公告)日:2004-09-30
    The present invention provides compounds of formula (I) 1 the prodrugs thereof, and the pharmaceutically acceptable salts of the compounds and prodrugs, wherein R a , R b , R 1 , and R 2 are as defined herein; pharmaceutical compositions thereof; and uses thereof.
    本发明提供了式(I)的化合物 1 的前药,以及所述化合物和前药的药学上可接受的盐,其中R a ,R b ,R 1 和R 2 如本文所定义;其药物组合物;以及其用途。
  • [EN] MUSCARINIC AGONISTS<br/>[FR] AGONISTES MUSCARINIQUES
    申请人:LILLY CO ELI
    公开号:WO2004094363A1
    公开(公告)日:2004-11-04
    The present invention relates to compounds of Formula (I): which are agonists of the M-1 muscarinic receptor.
    本发明涉及以下式(I)的化合物,它们是M-1肌胆碱受体的激动剂。
  • 一种用作吲哚胺2,3-双加氧酶的抑制剂的1, 2,5-噁二唑衍生物
    申请人:盛世泰科生物医药技术(苏州)有限公司
    公开号:CN110204537B
    公开(公告)日:2021-10-08
    本发明属于1,2,5‑噁二唑衍生物技术领域,具体涉及一种用作吲哚胺2,3‑双加氧酶的抑制剂的1,2,5‑噁二唑衍生物或其药学上可接受的盐。所述用作IDO抑制剂的1,2,5‑噁二唑衍生物或其药学上可接受的盐,其结构如下式Ⅰ所示:本发明提供了一种结构新颖的通式化合物I;实验结果表明,本发明提供的实施例中部分化合物同时具有优异IDO抑制活性及渗透性能。本发明提供的实施例化合物有望作为肿瘤分子免疫治疗药物上市用于癌症的治疗。
  • Novel N-acylated heterocycles
    申请人:Recordati S.A.
    公开号:US20030162777A1
    公开(公告)日:2003-08-28
    Described are compositions comprising a muscarinic receptor antagonist and an N-acylated heterocycle derivative having affinity for serotonergic receptors, and enantiomers, diastereoisomers, N-oxides, polymorphs, solvates and pharmaceutically acceptable salts thereof. The combination of a muscarinic receptor antagonist and an N-acylated heterocycle, or an enantiomer, diastereoisomer, N-oxide, polymorph, solvate or pharmaceutically acceptable salt thereof, is useful in the treatment of patients with neuromuscular dysfunction of the lower urinary tract and diseases related to 5-HT 1A receptors.
    描述了包含一种肌氨酸受体拮抗剂和一种对5-HT 1A 受体具有亲和力的N-酰化杂环衍生物的组合物,以及它们的对映体、二对映体、N-氧化物、多型体、溶剂合物和药用可接受盐。肌氨酸受体拮抗剂和N-酰化杂环,或其对映体、二对映体、N-氧化物、多型体、溶剂合物或药用可接受盐的组合,在治疗患有下尿路神经肌肉功能障碍和与5-HT 1A 受体相关疾病的患者中是有用的。
  • [EN] SUBSTITUTED 2H-[1,2,4]TRIAZOLO[4,3-A]PYRAZINES AS GSK-3 INHIBITORS<br/>[FR] 2H-[1,2,4]TRIAZOLO[4,3-A]PYRAZINES SUBSTITUEES EN TANT QU'INHIBITEURS DE LA GSK-3
    申请人:PFIZER PROD INC
    公开号:WO2005035532A1
    公开(公告)日:2005-04-21
    The invention relates to compounds of formula (I) prodrugs thereof, and the pahrmaceutically acceptabel salts of the compounds and prodrugs, wherein Ra, Rb, R1 and R2 are as defined herein; pharmaceutical compositions thereof; and uses thereof.
    这项发明涉及到式(I)化合物及其前药,以及该化合物和前药的药用可接受盐,其中Ra、Rb、R1和R2如本文所定义;药物组合物;以及它们的用途。
查看更多